| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6284804 | SANDOZ | Topical suspension formulations containing ciprofloxacin and dexamethasone |
Aug, 2020
(3 years ago) | |
| US6359016 | SANDOZ | Topical suspension formulations containing ciprofloxacin and dexamethasone |
Aug, 2020
(3 years ago) | |
| US9402805 | SANDOZ | Method of treating middle ear infections |
Sep, 2022
(1 year, 7 months ago) | |
| US9149486 | SANDOZ | Method of treating middle ear infections |
Sep, 2022
(1 year, 7 months ago) | |
| US9345714 | SANDOZ | Method of treating middle ear infections |
Sep, 2022
(1 year, 7 months ago) | |
| US8846650 | SANDOZ | Method of treating middle ear infections |
Jun, 2025
(1 year, 1 month from now) | |
Ciprodex is owned by Sandoz.
Ciprodex contains Ciprofloxacin; Dexamethasone.
Ciprodex has a total of 6 drug patents out of which 5 drug patents have expired.
Expired drug patents of Ciprodex are:
- US6284804
- US6359016
- US9402805
- US9149486
- US9345714
Ciprodex was authorised for market use on 18 July, 2003.
Ciprodex is available in suspension/drops;otic dosage forms.
Ciprodex can be used as treatment of acute otitis media, treatment of acute otitis externa.
The generics of Ciprodex are possible to be released after 04 June, 2025.
Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient
Market Authorisation Date: 18 July, 2003
Treatment: Treatment of acute otitis externa; Treatment of acute otitis media
Dosage: SUSPENSION/DROPS;OTIC
CIPRODEX family patents
